Therapeutic Antitumor Efficacy of Anti-CD137 Agonistic Monoclonal Antibody in Mouse Models of Myeloma
Open Access
- 1 November 2008
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 14 (21), 6895-6906
- https://doi.org/10.1158/1078-0432.ccr-08-0285
Abstract
Purpose: Eradication of post-treatment residual myeloma cells is needed to prevent relapses, and immunostimulatory monoclonal antibodies (mAb) such as anti-CD137, CTLA-4, CD40, etc., which enhance the immune response against malignancies, represent a means of achieving this purpose. This study explores anti-CD137 mAbs for multiple myeloma treatment in preclinical models of the disease because they safely augment tumor immunity and are in clinical trials for other cancers. Experimental Design: The antitumor effect of anti-CD137 mAb on mouse plasmacytomas derived from HOPC and NS0 cell lines was studied and compared with that of anti-CTLA-4, anti-CD40, and anti-ICAM-2 mAbs. The antitumor effect of anti-CD137 mAb was also examined in a mouse syngeneic disseminated myeloma (5TGM1) model, which more closely resembles human multiple myeloma. Depletions of specific cell populations and gene-targeted mice were used to unravel the requirements for tumor rejection. Results: Agonistic mAb against CD137 and blocking anti-CTLA-4 mAb showed activity against i.p. HOPC tumors, resulting in extended survival of mice that also became immune to rechallenge. Anti-CD137 mAbs induced complete eradications of established s.c. NS0-derived tumors that were dependent on IFN-γ, natural killer cells, and CD8+ T lymphocytes. Natural killer cells accumulated in tumor draining lymph nodes and showed increased IFN-γ production. Antitumor efficacy of anti-CD137 mAb was preserved in CD28-deficient mice despite the fact that CD28 signaling increases the expression of CD137 on CD8+ T cells. Importantly, anti-CD137 mAb treatment significantly decreased systemic tumor burden in the disseminated 5TGM1 model. Conclusions: The immune-mediated antitumor activity of anti-CD137 mAb in mouse models holds promise for myeloma treatment in humans.Keywords
This publication has 55 references indexed in Scilit:
- The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFNγInternational Journal of Cancer, 2007
- The Emerging Role of Targeted Therapy for Hematologic Malignancies: Update on Bortezomib and TipifarnibThe Oncologist, 2007
- Immunostimulatory monoclonal antibodies for cancer therapyNature Reviews Cancer, 2007
- Combination Therapy with Anti–CTL Antigen-4 and Anti-4-1BB Antibodies Enhances Cancer Immunity and Reduces AutoimmunityCancer Research, 2006
- Checkpoint Blockade in Cancer ImmunotherapyAdvances in Immunology, 2006
- Low Surface Expression of B7-1 (CD80) Is an Immunoescape Mechanism of Colon CarcinomaCancer Research, 2006
- Interfacing T-cell effector and regulatory function through CD137 (4-1BB) co-stimulationTrends in Immunology, 2005
- 4‐1BB enhances CD8+ T cell expansion by regulating cell cycle progression through changes in expression of cyclins D and E and cyclin‐dependent kinase inhibitor p27kip1European Journal of Immunology, 2003
- Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathwayEuropean Journal of Immunology, 1998
- CELLULAR RESPONSES TO INTERFERON-γAnnual Review of Immunology, 1997